Bart Spiesschart

Company: Boehringer Ingelhiem

Job title: Principal scientist In vivo Pharmacology

Bio:

Seminars:

Conventional Cancer Treatments to Enhance Anti-Tumour Immune Activation 2:30 pm

Are radiotherapy and chemotherapy viable options to combine with OV?

This roundtable will aim to discuss how the OV-combined tumor immunotherapy can be enhanced according to the tumor location and individual patient progress.

Day: Day One

Interactive Roundtable Discussions 3:00 pm

Day: Day One